2015 American Transplant Congress
CTLA4Ig Administered During T-Cell Priming Negates de novo Alloantibody Responses and Modulates Recall Antibody Production
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Arcadia, CA.
Background CTLA4Ig (Belatacept) is a novel anti-rejection therapy aimed at costimulatory blockade. Clinical data suggest that post-transplant alloantibody formation is also reduced in patients treated…2015 American Transplant Congress
Molecular Features of Kidney Transplant Biopsies Without Allograft Injury in Relation With Type of Induction Therapy
Objective: Molecular evidence of allograft injury might precede histopathological findings of allograft injury. We aimed to investigate if the type of induction therapy effect intragraft…2015 American Transplant Congress
Characterization of Peripheral Blood T and B Cells of Sensitized Kidney Transplant Recipients With Long Term Stable Graft Function
We examined the phenotype of T and B cells of peripheral blood of sensitized kidney transplant recipients with stable graft function (GFR > 29mL/min) enrolled…2015 American Transplant Congress
Eculizumab as a Rescue Therapy for Rhinovirus-Induced Antibody Mediated Rejection After Incompatible Kidney Transplantation
Northwestern University, Chicago, IL.
Background: Despite being an effective strategy for overcoming ABO and HLA incompatibilities, desensitized kidney transplantation still has limitations. Early antibody mediated rejection (ABMR) may be…2015 American Transplant Congress
CPRA Values Are Substantially Increased for Some Candidates Subsequent to Inclusion of Unacceptable C-locus (UA-C) Antigens While Listing Practices Remain Unchanged
1UNOS, Richmond; 2Emory University Hospital, Atlanta; 3Stanford University, Palo Alto.
Background: CPRA is the % of deceased donors expected to have one or more UAs with a given candidate. Prior to 12/5/13, candidates with UA-C…2015 American Transplant Congress
Post-Kidney Allograft Nephrectomy Anti-HLA Immunization Is Not Due to a Release of Anti-HLA Antibodies from the Failed Kidney
Background and aims: The reasons for the increased incidence of de novo anti-HLA donor specific antibodies (DSAs) that is observed after kidney allograft nephrectomy (NTx)…2015 American Transplant Congress
Cytomegalovirus and BK Infections in Sensitized Kidney Transplant Recipients
Department of Medicine, University of Wisconsin School of Medicine and Pubic Health, Madison.
Background:There is little information on the incidence, risk factors and outcomes associated with cytomegalovirus (CMV) and BK infections in sensitized patientsMethods:We examined 254 kidney transplant…2015 American Transplant Congress
What Can UNOS Data Tell Us About Patient Outcomes After Primary Renal Allograft Failure?
Evidence based approaches to patient care after Renal Allograft Failure do not exist, despite this being a high mortality period. Access to retransplantation is important…2015 American Transplant Congress
Left Ventricular Assist Device–Associated Allosensitization — Clinical Implications
U.T.A.H. Cardiac Transplant Program, Salt Lake City, UT.
Purpose: Allosensitization has been recognized as a prognostic marker of worse outcome after transplant. It is unclear, however, whether sensitization events that take place shortly…2015 American Transplant Congress
Are DQA Antibodies Real?
Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Antibodies specific for HLA-DQ antigens appear to be increasing in frequency in the post-transplant period and are difficult to reduce effectively with desensitization protocols using…
American Transplant Congress abstracts